MARKET

CRTX

CRTX

Cortexyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

56.36
+1.76
+3.21%
Opening 10:15 01/28 EST
OPEN
54.82
PREV CLOSE
54.60
HIGH
57.10
LOW
54.80
VOLUME
40.36K
TURNOVER
--
52 WEEK HIGH
72.94
52 WEEK LOW
19.35
MARKET CAP
1.47B
P/E (TTM)
-34.9293
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CRTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CRTX News

  • Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimers Disease
  • Business Wire.01/13 13:00
  • Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020
  • Business Wire.01/08 21:05
  • Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation
  • Simply Wall St..01/05 13:14
  • Last year's Bay Area IPO performances show why it pays to be an insider
  • American City Business Journals.01/03 15:15

More

Industry

Biotechnology & Medical Research
+1.31%
Pharmaceuticals & Medical Research
+0.62%

Hot Stocks

Name
Price
%Change

About CRTX

Cortexyme, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The Company is focused on a infectious pathogen tied to neurodegeneration in humans and animal models. The Company’s lead drug candidate, COR388, is an orally-administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer’s disease. COR388 is designed to target an upstream driver of multiple Alzheimer’s pathological pathways, including amyloid beta production, inflammation and neurodegeneration, in contrast to mechanisms of action targeting downstream effects, such as amyloid plaques and tau tangles.
More

Webull offers Cortexyme Inc (CRTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.